Lower cholesterol goals improve survival rates, new study shows

Heart disease remains one of the leading killers worldwide, gradually developing over many years as fatty deposits, known as plaques, accumulate inside arteries.

These plaques can cause arteries to narrow or become completely blocked, increasing the risk of serious health events such as heart attacks or strokes.

A central player in this process is low-density lipoprotein cholesterol, or LDL-C, frequently called “bad cholesterol” because elevated levels promote plaque formation in arteries.

For years, physicians have aimed to lower LDL-C to diminish heart disease risk. Nonetheless, debates have persisted over how low cholesterol levels should go to be effective.

Recent research, presented at the American College of Cardiology’s Annual Scientific Session, offers clearer guidance on this issue — particularly regarding how aggressively to lower cholesterol in patients already diagnosed with heart disease.

The study centered on individuals with atherosclerotic cardiovascular disease (ASCVD), which includes patients who have experienced events like heart attacks, strokes, or artery blockages. These individuals face a high likelihood of recurrence or worsening in the future.

Researchers tracked 3,048 patients from 17 hospitals in South Korea, with an average age of 64, and approximately 20% being women. All had documented heart disease and were considered high risk.

The participants were split into two groups: one targeted LDL-C levels below 55 mg/dL, while the second aimed for less than 70 mg/dL — a common goal used in many treatment guidelines.

Treatments were adjusted individually, utilizing common medications like statins, with additional drugs such as ezetimibe or newer therapies introduced to push cholesterol even lower when necessary.

After three years, results showed a notable advantage for the group targeting the lower LDL-C level. Only about 6.6% experienced major cardiac events, compared to 9.7% in the group with the less aggressive target—a risk reduction of roughly one-third.

This benefit primarily came from fewer heart attacks and fewer procedures to clear blocked arteries. Overall, the combined risk of heart attack, stroke, and cardiovascular death was also significantly reduced.

Lowering cholesterol more aggressively did not lead to an increase in side effects. Both groups experienced similar safety profiles, with no significant rise in muscle pain, diabetes risk, or blood sugar issues. Interestingly, some kidney function measures appeared slightly better in the more aggressive LDL-C lowering group.

The evidence suggests that setting a lower cholesterol target can provide extra protection for those with existing heart conditions. These findings were consistent across diverse patient subgroups, indicating broad applicability.

However, the study had limitations: it was conducted solely in South Korea, involving only East Asian participants, which might influence how applicable the results are to other populations. Additionally, some patients in the intensive treatment group did not reach the target levels, partly due to limited access to certain newer drugs.

Overall, this research strongly supports the concept that “lower is better” when it comes to LDL cholesterol in patients at high risk for cardiovascular events. It aligns with current guidelines advocating for more aggressive lipid management.

In simple terms, for individuals with pre-existing heart disease, reducing bad cholesterol to very low levels can significantly lower the chances of future cardiac issues. This insight may help doctors refine treatment plans and improve patient outcomes.

The study findings were shared at the American College of Cardiology’s Annual Scientific Session.

If you’re interested in health topics, consider exploring research on the benefits of low-dose lithium supplements and what is known about egg consumption and heart health.

For additional information, check out recent studies discussing potatoes and hypertension, or the top six bread choices recommended for people with heart disease.

Source: Yonsei University College of Medicine.